¼¼°èÀÇ Ã¶ ¾àÁ¦ ½ÃÀå
Iron Drugs
»óǰÄÚµå : 1655380
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 187 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,015,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,045,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ã¶ ¾àÁ¦ ½ÃÀåÀº 2030³â±îÁö 110¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 69¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Ã¶ ¾àÁ¦ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 7.9%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 110¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ °æ±¸Á¦´Â CAGR 9.2%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 67¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. IV ¾àÁ¦ ºÎ¹®Àº ºÐ¼® ±â°£ Áß CAGRÀÌ 6.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 18¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ã¶ ¾àÁ¦ ½ÃÀåÀº 2024³â¿¡ 18¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 28¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 11.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.9%¿Í 7.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ã¶ ¾àÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú Àü·«Àû ÀλçÀÌÆ®

öºÐ °áÇÌÁõ Ä¡·á¿¡ öºÐÁ¦°¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

öºÐÁ¦´Â öºÐ °áÇ̼º ºóÇ÷(IDA) µî öºÐ º¸ÃæÀÌ ÇÊ¿äÇÑ Ã¶ºÐ °áÇÌ ÁúȯÀÇ Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ö °áÇ̼º ºóÇ÷(IDA)À» ºñ·ÔÇÑ Ã¶ºÐ º¸ÃæÀÌ ÇÊ¿äÇÑ Áúȯ¿¡¼­ ö °áÇ̼º ºóÇ÷ Ä¡·áÁ¦(öºÐÁ¦)´Â Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. öºÐ °áÇÌÀº ºÒÃæºÐÇÑ ½Ä»ç, ¸¸¼º ÃâÇ÷, Èí¼ö Àå¾Ö ÁõÈıº µî ´Ù¾çÇÑ ¿øÀο¡ ÀÇÇØ ¹ß»ýÇϹǷΠöºÐÁ¦´Â ´Ù¾çÇÑ È¯ÀÚ±º¿¡¼­ Ä¡·á ÇÁ·ÎÅäÄÝÀÇ Áß¿äÇÑ ¿ä¼Ò·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. öºÐÁ¦°¡ Çì¸ð±Û·Îºó ¼öÄ¡¸¦ °³¼±Çϰí ÇÇ·Î¿Í ¼è¾à°¨°ú °°Àº Áõ»óÀ» ¿ÏÈ­ÇÏ´Â µ¥ È¿°úÀûÀ̶ó´Â »ç½ÇÀº ÀÓ»ó¿¡¼­ öºÐÁ¦ÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

»õ·Î¿î Á¦Á¦´Â ¾î¶»°Ô öºÐÁ¦ÀÇ È¿´ÉÀ» Çâ»ó½Ãų ¼ö Àִ°¡?

Ãֱ٠öºÐ Á¦Á¦ÀÇ Á¦Çü¿¡ ´ëÇÑ ÃÖ±Ù ¹ßÀüÀº ±× È¿´É°ú ³»¾à¼ºÀ» Çâ»ó½ÃŰ°í ±âÁ¸ öºÐ º¸ÃæÁ¦ÀÇ ÇѰè Áß ÀϺθ¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ´Ù´ç·ù-ö º¹ÇÕü Á¦Á¦ ¹× Çðö Æú¸®ÆéƼµå Á¦Á¦ÀÇ °³¹ßÀº ¼ÒÈ­°ü³» öºÐ Èí¼ö¸¦ °³¼±Çϰí Ȳ»êÁ¦ÀÏö°ú °°Àº ±âÁ¸ ö¿°¿¡¼­ ÈçÈ÷ ¹ß»ýÇÏ´Â ¼ÒÈ­±â ºÎÀÛ¿ëÀ» ÁÙ¿´½À´Ï´Ù. ¶ÇÇÑ Ä«¸£º¹½Ã¸»Åä¿À½º öºÐÁ¦Á¦³ª ÀÚ´ç öºÐÁ¦Á¦¿Í °°Àº Á¤¸ÆÁÖ»ç öºÐÁ¦Á¦ÀÇ µµÀÔÀº ƯÈ÷ ÁßÁõ ºóÇ÷ ȯÀÚ³ª °æ±¸¿ë öºÐÁ¦Á¦¸¦ º¹¿ëÇÒ ¼ö ¾ø´Â ȯÀڵ鿡°Ô º¸´Ù ºü¸£°í È¿À²ÀûÀ¸·Î öºÐÀ» º¸ÃæÇÒ ¼ö ÀÖ´Â ¼ö´ÜÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ »õ·Î¿î Á¦Á¦´Â ÀÇ·áÁøÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â Ä¡·á ¿É¼ÇÀÇ ÆøÀ» ³ÐÇô öºÐ °áÇÌÀ» º¸´Ù °³ÀÎÈ­µÇ°í È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

öºÐ Ä¡·á¿¡´Â ¾î¶² ¹®Á¦°¡ ÀÖÀ¸¸ç, ¾î¶»°Ô ´ëóÇϰí Àִ°¡?

öºÐÁ¦ Ä¡·á´Â È¿°úÀûÀÌÁö¸¸ ¹®Á¦°¡ ¾ø´Â °ÍÀº ¾Æ´Õ´Ï´Ù. °¡Àå ÈçÇÑ ¹®Á¦ Áß Çϳª´Â °æ±¸¿ë öºÐÁ¦ º¹¿ë°ú °ü·ÃµÈ À§Àå Àå¾Ö·Î ÀÎÇØ ȯÀÚÀÇ ¼øÀÀµµ°¡ ¶³¾îÁú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ´õ Àß °ßµô ¼ö ÀÖ´Â »õ·Î¿î Á¦ÇüÀÌ °³¹ßµÇ°í ÀÖÀ¸¸ç, ȯÀÚµéÀº ½Ä»ç¿Í ÇÔ²² º¸ÃæÁ¦¸¦ ¼·ÃëÇÏ´Â µî ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â ¹æ¹ýÀ» ±³À°¹Þ°í ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ¹®Á¦´Â ƯÈ÷ Àå±â Ä¡·á¸¦ ¹Þ´Â ȯÀÚ³ª Ç÷»ö¼ÒÄ§ÂøÁõ°ú °°Àº ÁúȯÀ» ¾Î°í Àִ ȯÀÚ¿¡¼­ öºÐ °ú´ÙÁõÀÇ À§Ç輺ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ À§ÇèÀ» ÁÙÀ̱â À§Çؼ­´Â öºÐ ¼öÄ¡¸¦ ¸é¹ÐÈ÷ ¸ð´ÏÅ͸µÇÏ°í °³º°ÀûÀÎ Åõ¿© Àü·«À» ¼ö¸³ÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¶ÇÇÑ »õ·Î¿î Á¤¸Æ³» öºÐÁ¦ÀÇ ºñ¿ë°ú °¡¿ë¼ºÀº ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ ÀϺΠȯÀÚ¿¡°Ô´Â À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ±Øº¹Çϱâ À§Çؼ­´Â Àú·ÅÇÑ Ã¶ºÐ ¿ä¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϰí ÀÇ·áÁø¿¡°Ô º£½ºÆ® ÇÁ·¢Æ¼½º¸¦ ±³À°ÇÏ´Â ³ë·ÂÀÌ ÇʼöÀûÀÔ´Ï´Ù.

ö ¾àÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

öºÐÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº öºÐ °áÇÌ ¹× °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡, ½Å±Ô ¹× °³¼±µÈ Á¦Á¦ °³¹ß, ½ÅÈï ±¹°¡ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¿©¼º, ¾î¸°ÀÌ, ³ë³âÃþ¿¡¼­ ºóÇ÷¿¡ ´ëÇÑ Àü ¼¼°è ºÎ´ãÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀΠöºÐ ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Èí¼öÀ²ÀÌ ³ô°í ºÎÀÛ¿ëÀÌ ÀûÀ¸¸ç È¿°ú°¡ ´õ »¡¸® ³ªÅ¸³ª´Â ÷´Ü Á¦Á¦ÀÇ µµÀÔÀº º¸´Ù È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ã¶ºÐ °áÇÌÀÇ Á¶±â Áø´Ü°ú Á¶±â Ä¡·áÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í °³¹ßµµ»ó±¹¿¡¼­ÀÇ ÀÇ·á ¼­ºñ½º È®´ë°¡ öºÐÁ¦Á¦ »ç¿ëÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ´õ ¸¹Àº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ÀÌ·¯ÇÑ »õ·Î¿î Ä¡·á¹ýÀ» äÅÃÇϰí ȯÀÚµéÀÌ ´õ ¸¹Àº Á¤º¸¸¦ ¾ò°Ô µÊ¿¡ µû¶ó öºÐÁ¦ ½ÃÀåÀº °è¼Ó »ó½Â¼¼¸¦ À̾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(°æ±¸¾à, Á¤¸ÆÁÖ»çÁ¦)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 28»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Iron Drugs Market to Reach US$11.0 Billion by 2030

The global market for Iron Drugs estimated at US$6.9 Billion in the year 2024, is expected to reach US$11.0 Billion by 2030, growing at a CAGR of 7.9% over the analysis period 2024-2030. Oral Drugs, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth in the IV Drugs segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 11.9% CAGR

The Iron Drugs market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 11.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Iron Drugs Market - Key Trends & Strategic Insights

Why Are Iron Drugs Essential in Treating Iron Deficiency Disorders?

Iron drugs play a critical role in the treatment of iron deficiency disorders, including iron deficiency anemia (IDA) and other conditions where iron supplementation is necessary. These drugs are used to replenish the body's iron stores, enabling the production of hemoglobin and the proper functioning of red blood cells. Iron deficiency can result from various causes, such as inadequate dietary intake, chronic blood loss, or malabsorption syndromes, making iron drugs a key component of treatment protocols across different patient populations. The effectiveness of iron drugs in improving hemoglobin levels and alleviating symptoms such as fatigue and weakness underscores their importance in clinical practice.

How Are New Formulations Enhancing the Efficacy of Iron Drugs?

Recent advancements in iron drug formulations are enhancing their efficacy and tolerability, addressing some of the limitations of traditional iron supplements. For example, the development of polysaccharide-iron complex and heme iron polypeptide formulations has improved the absorption of iron in the gastrointestinal tract, reducing the gastrointestinal side effects that are common with older iron salts like ferrous sulfate. Additionally, the introduction of intravenous (IV) iron preparations, such as ferric carboxymaltose and iron sucrose, offers a faster and more efficient means of replenishing iron stores, particularly in patients with severe anemia or those who cannot tolerate oral iron. These new formulations are expanding the range of treatment options available to healthcare providers, allowing for more personalized and effective management of iron deficiency.

What Challenges Are Associated with Iron Drug Therapy, and How Are They Being Addressed?

Iron drug therapy, while effective, is not without challenges. One of the most common issues is the gastrointestinal discomfort associated with oral iron supplements, which can lead to poor patient adherence. To address this, newer formulations with better tolerability are being developed, and patients are being educated on how to minimize side effects, such as by taking supplements with food. Another challenge is the risk of iron overload, particularly in patients receiving long-term therapy or those with conditions like hemochromatosis. Careful monitoring of iron levels and individualized dosing strategies are essential to mitigate this risk. Additionally, the cost and availability of newer IV iron formulations can be a barrier for some patients, particularly in low-resource settings. Efforts to increase access to affordable iron therapies and educate healthcare providers on best practices are crucial to overcoming these challenges.

Which Factors Are Propelling the Growth of the Iron Drugs Market?

The growth of the iron drugs market is driven by several factors, including the increasing prevalence of iron deficiency and related disorders, the development of new and improved formulations, and the expansion of healthcare infrastructure in emerging markets. As the global burden of anemia continues to rise, particularly among women, children, and the elderly, the demand for effective iron therapies is growing. The introduction of advanced formulations that offer better absorption, fewer side effects, and faster results is also driving market growth by providing more effective treatment options. Additionally, the growing awareness of the importance of early diagnosis and treatment of iron deficiency, coupled with the expansion of healthcare services in developing regions, is increasing the uptake of iron drugs. As more healthcare providers adopt these newer therapies and as patients become more informed about their options, the iron drugs market is expected to continue its upward trajectory.

SCOPE OF STUDY:

The report analyzes the Iron Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Oral Drugs, IV Drugs)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 28 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â